Systemic administration of L-arginine alters renal haemodynamics in humans. We examined whether L-arginine-induced vasodilation of the renal vasculature is related to an increased production and release of NO by comparing the effects of L-and D-arginine on renal endotheliumdependent vasodilation. In a double-blind randomized cross-over study including 20 young, healthy male white subjects (age 26p2 years), we determined the effects of intravenous administration of L-arginine or its enantiomer D-arginine, at doses of 100 mg/kg body weight for 30 min or 500 mg/kg for 30 min, on renal haemodynamics. Renal plasma flow (RPF) and glomerular filtration rate (GFR) were assessed by a constant-infusion input-clearance technique (using p-aminohippuric acid and inulin respectively). In addition, changes in blood pressure, heart rate, urinary sodium excretion (U Na ) and urinary cGMP were measured. HPLC was used to determine L-and D-arginine concentrations. Intravenous infusion of L-arginine at 100 mg/kg for 30 min increased RPF from 641p87 to 677p98 ml/min (P l 0.019), whereas infusion of Darginine did not (from 642p74 to 657p86 ml/min ; not significant). The change in RPF was more marked during the infusion of L-arginine than during the infusion of D-arginine (j36p61 versus j16p57 ml/min ; P l 0.037). Infusion of both L-and D-arginine at doses of 500 mg/kg for 30 min increased RPF from baseline [from 641p87 to 762p133 ml/min (P 0.001) and from 642p74 to 713p120 ml/min (P l 0.004) respectively], but the change in RPF again was greater in response to L-arginine infusion than to infusion with D-arginine (j121p97 versus j71p94 ml/min ; P l 0.018). In accordance, changes in renal vascular resistance (RVR) were higher in response to Larginine compared with D-arginine for both doses (P 0.05 and P 0.001 respectively). U Na increased only with L-arginine (change in U Na , j0.33p0.26 mmol/min ; P 0.01) but not with Darginine (change in U Na , j0.11p0.17 mmol/min ; not significant). The change in U Na was more pronounced during infusion of L-arginine compared with infusion of D-arginine (P l 0.023). In parallel, urinary excretion of cGMP only increased in response to L-arginine (j676p272 pmol/l ; P l 0.038) and not during D-arginine infusion (j185p153 pmol/l ; not significant). L-Arginineinduced changes in RPF, RVR, U Na and cGMP excretion differed significantly from those induced by D-arginine. Thus although no direct measurements of NO synthesis were performed, putative markers of NO synthesis suggest that the renal vasodilatory response to L-arginine, at least in part, was due to increased production and release of NO. The dose of L-arginine at 100 mg/kg for 30 min emerged as the most suitable, because of the absence of systemic haemodynamic changes. The effects of infusion of L-arginine at 500 mg/kg for 30 min on renal endothelium-dependent vasodilation need to be corrected for the effects of D-arginine before conclusions can be drawn.
INTRODUCTION
The endothelium plays an exceedingly important role in the regulation of the vascular tone in humans, which has been attributed to the release of endothelium-derived vasoactive substances [1] . Attenuated endothelium-dependent vasodilation has been demonstrated in patients with various cardiovascular risk factors, i.e smoking [2] , diabetes mellitus [3] , arterial hypertension [4] and hypercholesterolaemia [5] . The impaired endothelium-dependent vasodilation has been linked to an interference with the L-arginine\NO pathway in several trials in which the human forearm vasculature was examined [3] [4] [5] . The observation that endothelial function was impaired without histological evidence of atherosclerotic lesions [6] lead to the concept that endothelial dysfunction is an early event in the pathogenesis of atherosclerosis, and its identification therefore represents an important diagnostic tool.
L-Arginine is the physiological precursor of NO, a mediator released by vascular endothelial cells that, to a great extent, accounts for the biological activity of endothelium-derived relaxing factor [5, 7] . The synthesis of NO is stereospecific, with the NO synthase enzyme cleaving NO from L-arginine, whereas the enantiomer Darginine is not a substrate for the enzyme [8] . The effects of NO on target cells usually occur through activation of smooth-muscle-cell soluble guanylate cyclase and an increase in intracellular cGMP, resulting in relaxation of vascular tone [9] and natriuresis [10] . In addition, NO inhibits platelet aggregation [11] and adhesion [12] , as well as smooth-muscle-cell proliferation [13] , thereby counteracting pathogenetic mechanisms involved in the development of atherosclerosis.
Systemic intravenous infusion of L-arginine in healthy subjects lowers mean arterial blood pressure with a concurrent increase in heart rate, decreases peripheral arteriolar resistance and inhibits platelet aggregation [2, 14, 15] . The important role of the L-arginine\NO pathway in the regulation of renal haemodynamics has been demonstrated in humans and rats by infusion of the NO synthase inhibitor, N ω -nitro-L-arginine methyl ester (L-NAME), which reduced renal blood flow [10, 16, 17] . In contrast to normotensive subjects, systemic infusion of L-arginine did not increase renal plasma flow (RPF) in subjects with mild essential hypertension, suggesting a dysfunction of the L-arginine\NO pathway in this population [18] . This hypothesis was further supported by Mimran et al. [19] , who documented an increase in RPF and plasma cGMP in response to systemic infusion of L-arginine in normotensive subjects, which was abolished in untreated hypertensive subjects but restored after treatment with angiotensin-converting enzyme inhibitors.
L-Arginine-induced vasodilation has been suggested to be mediated by an increase in NO synthesis, since an increase in certain putative markers for NO synthesis, such as plasma cGMP [14, 20] , plasma L-citrulline [20, 21] and urinary excretion of NO $ − , was observed during systemic L-arginine infusion [14, 15] . However, Smulders et al. [22] compared the haemodynamic and biochemical responses to infusion of L-arginine with L-lysine (which is not a substrate for NO synthesis). L-Lysine-induced effects were found to be similar to those of L-arginine infusion with respect to changes in plasma cGMP, plasma L-citrulline and plasma electrolytes, but vasodilation was not observed in response to L-lysine infusion. The authors concluded that these findings indirectly supported the hypothesis that vasodilation during Larginine infusion might be mediated by an increase in NO synthesis, but that the presumed biochemical markers for NO synthesis do not accurately reflect an increased production and release of NO.
Although applied by several investigators, the use of systemic administration of L-arginine as a test for endothelium-dependent vasodilation in the renal vascular bed has raised some criticism, since systemic infusion of other amino acids, which are not substrates for NO synthesis, also causes vasodilation in various vascular beds [23] , including the renal vasculature [24] . However, infusion of L-arginine is a safe method for the study of endothelium-dependent vasodilation compared with blockade of NO synthase by N G -monomethyl-L-arginine (L-NMMA) or L-NAME, with their potentially serious side effects, particularly in subjects with changes in the L-arginine\NO pathway, which are suggested to exist in hypertension, diabetes mellitus or hypercholesterolaemia. We therefore conducted this doubleblind, randomized, cross-over clinical study in 20 young, healthy, male, white subjects to investigate the effects on renal haemodynamics of an intravenous infusion of Larginine as opposed to those of its enantiomer D-arginine. An attempt was made to separate stereospecific, i.e. NOrelated effects from the non-specific effects arising from the infusion of an amino acid, and to examine the validity of L-arginine infusion to test renal endothelium-dependent vasodilation in humans.
METHODS

Study cohort
Our study population consisted of 20 healthy, young, white males (aged 26p2 years) who were recruited from the campus of the University of Erlangen-Nu$ rnberg. Inclusion criteria were age 18-30 years, fasting serum LDL-cholesterol concentration 130 mg\dl, fasting serum triacylglycerol concentration 200 mg\dl, fasting plasma glucose 110 mg\dl, serum creatinine concentration 1.2 mg\dl, and absence, or no history, of any cardiovascular risk factors, including arterial hypertension, hypercholesterolaemia, diabetes mellitus, smoking or any other chronic or acute cardiovascular, hepatic or renal disease. To ensure that all subjects were normotensive, casual as well as 24-h ambulatory blood pressure readings were performed (SpaceLabs 90207, Redmond, WA, U.S.A.), as outlined in detail previously [25] . All participants were given a thorough physical examination and an extensive laboratory work-up was performed as described in detail previously [26] . Before enrolment in the study, informed written consent was obtained from each participant and the study protocol was approved by the Ethical and Investigation Committee of the University of Erlangen-Nu$ rnberg.
Study protocol
L-Arginine-and D-arginine-induced vasodilation of the renal vasculature was assessed as part of a clearance infusion protocol. Subjects were randomly assigned to receive either L-or D-arginine on the first study day. The second study, with an identical protocol, was performed 2 weeks after the first study day. To determine RPF and glomerular filtration rate (GFR), the constant-infusion input-clearance technique, suggested by Cole et al. [27] , was applied. The advantage of this technique lies in the avoidance of bladder catheterization or reliance on spontaneous voiding. This method has recently been revalidated [28, 29] , and it was found to be reliable for young and middle-aged subjects with normal renal function. In brief, subjects fasted overnight for at least 12 h and were kept in a supine position in a quiet, dark and temperature-controlled (22-25 mC) room throughout the study. A catheter was inserted into the left antecubital vein for infusion of p-aminohippuric acid (PAH), inulin, L-arginine or D-arginine. A second catheter was inserted into the right antecubital vein to obtain blood samples. After a priming dose of PAH (sodium salt) (Nephrotest2 ; Merck Sharp & Dohme, Herts., U.K.) and inulin (Inutest2, Fresenius, Graz, Austria) that was adjusted according to body weight [28] , a constant infusion of both tracer substances was given to achieve steady-state conditions.
After a resting phase of 120 min, the infusion of either L-arginine (L-arginine hydrochloride ; Braun, Melsungen, Germany) or D-arginine (D-arginine hydrochloride ; Clinalfa, La$ ufelfingen, Switzerland) was initiated. Infusions were prepared immediately before administration. Both L-and D-arginine were administered at two dose levels, using an infusion pump (Infusomat, Braun, Melsungen, Germany) ; the first was 100 mg\kg for 30 min and the second 500 mg\kg for 30 min. Previously [28, 29] , it was found that, after 30 min, the steady state of PAH and inulin concentrations had changed, thereby allowing the measurement of RPF and GFR during provocative manoeuvres. The clearance study was then completed by a further 1 h rest period. The hydrochloride of L-arginine and D-arginine was used instead of the free base preparations, because alkaline buffers have been reported to stimulate the release of NO from cultured bovine aortic endothelial cells [30] . During the clearance study, 0.9 % physiological saline solution was co-infused at a constant rate of 125 ml\h to ensure constant urine flow. At the end of each phase, blood samples were drawn to measure serum PAH and inulin concentrations, and subjects were asked to void urine in a recumbent position and samples were used for the measurement of urinary sodium (U Na ) and cGMP excretion. Throughout the infusion protocol, blood pressure and heart rate were monitored at fixed intervals (every 5 min) using an oscillometric device (Dinamap ; Johnson & Johnson, Norderstedt, Germany). The time interval was changed to one measurement\min 5 min before the collection of blood samples, and mean values were computed from five consecutive measurements. All clearance protocols were performed in the morning, between 08:00 and 12:00 h. PAH was quantified according to the modification of Smith et al. [31] . Inulin was measured indirectly by converting inulin to fructose ; fructose was then estimated enzymically (Boehringer Mannheim, Mannheim, Germany) [32] . Measurements were made in duplicate for each blood sample and the coefficients of variation were 5 %. Urinary cGMP was measured by RIA [33] . Serum L-arginine concentrations were obtained using HPLC [34] at the Department of Clinical Chemistry and Laboratory Medicine, University of Regensburg, Germany.
Statistics
All statistical analyses were carried out using the SPSS software package [35] . Unpaired Student's t tests were used for comparison of different groups. Paired Student's t test analysis was performed to compare changes within groups. Multiple analysis of variance (MANOVA) was applied to test differences in dose-response curves between the groups. Pearson correlation coefficients were calculated when indicated. Unless otherwise specified, values are expressed as meanspS.D. A two-tailed P value 0.05 was considered to be significant.
RESULTS
Study population
Baseline characteristics of the study population are depicted in Table 1 . The study design meant that only young, healthy, male, white subjects were included. Therefore, total cholesterol and low-and high-density lipoprotein-cholesterol levels were in the normal range. None of the subjects had a history of arterial hypertension, which was further excluded by 24-h ambulatory blood pressure monitoring. All participants had normal kidney function according to serum creatinine and GFR.
Only non-smokers were included in our study. None of the subjects was on any regular medication or followed any specific dietary guidelines.
Effects of L-and D-arginine on systemic haemodynamics
The impact of L-arginine on blood pressure and heart rate is shown in Table 2 . Mean arterial blood pressure and heart rate at baseline were similar before the administration of either L-or D-arginine. A dose of 100 mg\kg for 30 min of either L-or D-arginine did not affect blood pressure when compared with baseline levels. At a dose of 500 mg\kg for 30 min, L-arginine but not D-arginine decreased mean arterial blood pressure when compared with baseline levels (P l 0.003), and this resulted in a significant decrease in mean arterial blood pressure when L-arginine was compared with D-arginine (P 0.001).
Changes in mean arterial pressure differed between L-and D-arginine for the doses tested (MANOVA Table 2 Impact of D-and L-arginine infusion on systemic haemodynamics
Values are expressed as meanspS.D. ***, P 0.001 from baseline. Abbreviations : MAP ; mean arterial pressure ; HR, heart rate ; p.i., post infusion ; ∆, change in ; n.s., not significant. Effects of L-and D-arginine on renal haemodynamics at a dose of 100 mg/kg for 30 min
Effects on renal haemodynamic data are given in Table 3 .
Compared with baseline measurements, RPF increased in response to the administration of L-arginine at 100 mg\kg for 30 min (P l 0.019), but not in response to D-arginine ( Table 3 ). The increase in RPF in response to L-arginine was more marked than the change in response to D-arginine (P l 0.037) (Figure 1 ). However, the increase in renal blood flow from baseline occurred only with L-arginine (P 0.05), and changes in renal blood flow in response to L-arginine were more marked compared with D-arginine (P l 0.036). Renal vascular resistance decreased only in response to L-arginine (P 0.05). GFR increased with both L-arginine (P 0.001) and D-arginine (P 0.05) compared with baseline (Table  3) . Changes in GFR from baseline were similar in response to L-or D-arginine administration. The filtration fraction was unchanged regardless of whether L-or D-arginine was given at 100 mg\kg for 30 min.
Effects of L-and D-arginine on renal haemodynamics at a dose of 500 mg/kg for 30 min
Compared with baseline measurements, an increase in RPF was observed after the administration of L-arginine (P l 0.001) or D-arginine (P l 0.004) at 500 mg\kg for 30 min. The increase in RPF in response to L-arginine was more marked than the change in response to D-arginine (P l 0.018) (Figure 1 ). Changes in RPF differed for all 
Effects of L-and D-arginine on U Na and cGMP
Because of difficulties with voiding urine or that urine volumes were too small for analysis, samples were obtained from 11 subjects only at baseline and after infusion of both L-and D-arginine at 500 mg\kg for 30 min. Compared with baseline values, U Na increased only with L-arginine (P l 0.002) but not with D-arginine (MANOVA P 0.01) ( Table 3 ). The increase in U Na in response to L-arginine was more marked than the change in response to D-arginine (P l 0.023 ; MANOVA P 0.05). Urinary cGMP concentration increased in response to L-arginine (P l 0.038 ; MANOVA P 0.05) but not to D-arginine, when compared with baseline values (Table 4) . cGMP levels differed after infusion of Lor D-arginine at 500 mg\kg for 30 min (P l 0.029 ; MANOVA P 0.03) (Figure 2 ).
Effects of L-and D-arginine on serum osmolarity and L-and D-arginine concentration
Serum osmolarity in response to L-and D-arginine at 100 mg\kg for 30 min did not increase compared with baseline measurements (Table 4) . For both L-and D-arginine at 500 mg\kg for 30 min an increase in serum osmolarity was observed (P 0.001). Changes in serum osmolarity did not differ after L-or D-arginine infusion (Table 4) . Baseline levels of L-arginine were in the physiological range of 50-150 µmol\l (79.9p17.4 µmol\l). Infusions of L-arginine at 100 mg\ kg for 30 min or 500 mg\kg for 30 min lead to a significant increase in serum L-arginine concentration (each P 0.001). Infusions of D-arginine at a dose of 100 mg\kg for 30 min or 500 mg\kg for 30 min induced a significant increase in serum D-arginine levels (each P 0.001) (Table 4) . Interestingly, the L-arginine concentration also increased in response to the infusion of D-arginine at 500 mg\kg for 30 min (from 72.2p22.5 to 92.2p26.3 µmol\l; P 0.01). This effect was not observed at a dose of 100 mg\kg for 30 min (from 72.2p22.5 to 79.3p22.6 µmol\l ; not significant).
DISCUSSION
L-Arginine is the physiological substrate for the formation of endothelium-derived NO. Vasodilatory effects in response to the administration of L-arginine therefore have been attributed to increased synthesis of endogenous NO. The vasodilatory effects of L-arginine have been demonstrated in various vascular beds, but this has not been found uniformly in all studies [36] . However, the following data clearly support the concept of an L-arginine-induced vasodilation due to an increase in NO production and release. In the forearm vasculature of healthy subjects, Imaizumi et al. [38] showed an L-arginine-induced vasodilation that was not evident with D-arginine infusion, thereby suggesting that L-arginineinduced effects were mediated through an increase in NO synthesis. Furthermore, acetylcholine-induced endothelium-dependent vasodilation is increased by concomitant administration of L-arginine in the forearm of healthy subjects [38, 39] , and in the coronary vascular bed [40] . In hypercholesterolaemic subjects, impaired endotheliumdependent vasodilation in response to acetylcholine was also improved by concomitant infusion of L-arginine in the forearm vasculature [41, 42] and in coronary circulation [43] . Again, this was not observed with concomitant infusion of D-arginine [40] , supporting the hypothesis of an impaired L-arginine\NO pathway in the peripheral and coronary vasculature of hypercholesterolaemic patients. Furthermore, several studies found increased concentrations of products from L-arginine metabolism during infusion of L-arginine, such as L-citrulline levels [20] , urinary excretion of nitrites, nitrates and cGMP [14, 44, 45] and exhaled NO [46] . Several investigators have applied systemic infusion of L-arginine as a non-invasive tool to assess endotheliumdependent vasodilation in the renal vascular bed [18, 19] . However, the stereospecific, i.e. NO-related effects of systemic L-arginine infusion on the renal vasculature have not yet been validated in humans. This issue is of particular importance, bearing in mind that several studies have shown vasodilatory properties of disparate amino acids that are not a substrate for NO synthesis [23, 24, 47] . Thus the crucial question of whether Larginine-induced vasodilation in the renal vasculature is due to NO-related effects or to non-specific effects of the amino acid infusion was examined in the present study. In our double-blind cross-over study the renal haemodynamic effects of L-arginine and its enantiomer Darginine were compared. Two different doses of L-and D-arginine (100 mg\kg for 30 min and 500 mg\kg for 30 min) were used to address the question of whether a small dose elicits effects on renal haemodynamics without affecting systemic haemodynamics. This allowed us to analyse the renal effects of L-arginine infusion without confounding changes in mean arterial pressure or heart rate [14, 15] . We found that changes in RPF and GFR in response to infusion of L-arginine were greater at both doses than those induced by the corresponding dose of D-arginine. However, when given the higher dose of D-arginine (500 mg\kg for 30 min), an increase in RPF and GFR was also observed.
This finding indicates that L-arginine-induced vasodilation in the human renal vasculature cannot be related exclusively to specific NO-related effects, but is also due to the oncotic effect of the amino acid per se, a criticism that has also been shared by other authors [48, 49] . Indeed, administration of the higher dose of each amino acid (L-and D-arginine at 500 mg\kg for 30 min) significantly increased serum osmolarity. The presence of non-specific, NO-unrelated effects is also supported by our measurement of L-and D-arginine serum concentrations. The dose of L-arginine at 500 mg\kg for 30 min lead to an approx. 100-fold increase in L-arginine serum levels with absolute concentrations being as high as 7397 µmol\l. Of note, serum L-arginine concentrations above 5000 µmol\l have been shown to produce nonstereospecific reductions in the tone of isolated blood vessels in vitro and in vascular beds in vivo [48] . Thus the administration of L-arginine at 100 mg\kg for 30 min emerged as the more appropriate dose to test renal endothelium-dependent vasodilation, since this dose of L-arginine increased serum L-arginine concentrations only from 79.9p17.4 to 952p259 µmol\l, thereby avoiding additional non-specific effects due to extensively increased L-arginine concentrations. Interestingly, L-arginine concentration also increased in response to the infusion of D-arginine at 500 mg\kg for 30 min (Table  4) . This finding supports the hypothesis that part of the D-arginine-induced vasodilatory effects are through its possible conversion to L-arginine.
In a previous study, L-arginine caused the release of insulin, glucagon, growth hormone, prolactin and somatostatin, but a similar effect occurred with both Land D-enantiomers [48] . Thus any difference in the effects of D-and L-arginine observed in the present study are unlikely to be related to induced changes in endocrine parameters.
Taken together, the effects of D-arginine can possibly be attributed to non-specific oncotic effects [49] , as seen with other amino acids, its possible conversion to Larginine and the release of endocrine substances [48] . Nevertheless, the more marked increase in RPF in response to L-arginine at 500 mg\kg for 30 min compared with D-arginine infusion suggests that a substantial portion of the renal vasodilation is mediated by NOrelated effects.
Higashi et al. [18] also found an increase in RPF in response to L-arginine at 500 mg\kg for 30 min in normotensive control subjects, whereas, in mildly hypertensive subjects, RPF did not increase. However, a hypotensive effect for L-arginine was documented in both normotensive and hypertensive subjects. Thus the renal circulation appeared to be particularly sensitive to modulation of the L-arginine\NO pathway [16, 37] . A study conducted by Mimran et al. [19] confirmed that the renal vasodilatory response to L-arginine was decreased or even abolished in untreated hypertensive subjects compared with normotensive subjects. Interestingly, the response of RPF to L-arginine was restored only by antihypertensive treatment with angiotensin-converting enzyme inhibitors but not with other antihypertensive agents. Only recently, this finding was confirmed by Higashi et al. [50] , who found that inhibition of angiotensin-converting enzyme, but not calcium antagonism, improved the response of the renal vasculature to L-arginine at 500 mg\kg for 30 min in patients with essential hypertension. The increase in L-arginineinduced renal vasodilation has been attributed to the effects of angiotensin-converting enzyme inhibition, namely the inhibition of bradykinin degradation [10] .
In the present study, a natriuretic effect of L-arginine infusion was also observed, as previously reported [15] . The natriuretic effect due to L-arginine infusion was found to be more marked compared with the response to D-arginine infusion. Conversely, systemic administration of the NO synthase inhibitor L-NMMA has been found to decrease U Na [10] . Thus the concept is proposed that L-arginine increases the synthesis of NO in renal tubular cells.
In the present study, L-arginine, but not D-arginine, infusion at a dose of 500 mg\kg for 30 min reduced mean arterial blood pressure. The hypotensive effect of L-arginine is in agreement with previous findings [15, 19, 47] . However, MacAllister et al. [48] did not observe changes in blood pressure in response to infusion of 10 g of L-arginine (i.e. a dose of approx. 150 mg\kg), which may be explained, most probably, by the rather low dose of L-arginine. In accord with this, we observed no effect on blood pressure by infusion of L-arginine at a dose of 100 mg\kg for 30 min. Thus the use of 100 mg\kg for 30 min of L-arginine appeared to be the preferable dose for testing endothelium-dependent vasodilation of the renal vascular bed, since no confounding effects due to changes in renal perfusion pressure would be present. However, systemic vascular resistance was not measured in the present study. Heart rate and blood pressure were monitored throughout the study period and, as shown in Table 2 , changes in mean arterial pressure and heart rate were similar with L-or D-arginine at a dose of 100 mg\kg for 30 min. Compared with baseline levels, an increase in heart rate was observed in response to L-arginine at a dose of 100 mg\kg for 30 min. Whether the observed increase in heart rate and a potential increase in cardiac index may have compensated for a possible decrease in systemic vascular resistance cannot be determined from our study. However, renal blood flow and RVR differed significantly between L-and D-arginine at a dose of 100 mg\kg for 30 min. Therefore it seems unlikely that the changes in renal haemodynamics are merely a reflection of possible changes in systemic vascular resistance.
Interestingly, heart rate increased in both groups at a dose of 500 mg\kg for 30 min, although blood pressure only decreased with L-arginine. After the termination of the study, it was revealed that some of the subjects receiving D-arginine complained of mild to moderate nausea, which was not noted during administration of L-arginine. The increase in heart rate in response to D-arginine, therefore, might be attributable to the occurrence of nausea.
The approach of using urinary cGMP levels as an indicator of an increased NO formation needs to be evaluated critically, since cGMP overflow in the urine is neither specific nor extremely sensitive for NO synthesis and release. cGMP may derive from other metabolic sources, since it is also the second messenger for ANP. Only recently, Sala et al. [51] reported a significant rise in urinary cGMP in response to acute volume loading with physiological saline solution. This effect was associated with increases in plasma atrial natriuretic peptide levels. Excess substrate supply with L-arginine, at the doses used in the present study, also leads to slight extracellular volume expansion, as indicated by changes of serum osmolarity due to L-and D-arginine infusion. Thus an increase in urinary cGMP poorly reflects increased NO synthesis and release. Since, in the present study, an increase in urinary cGMP was observed in response to L-arginine but not to D-arginine infusion (500 mg\kg for 30 min), part of the increase in urinary cGMP might be related to NO release and production stimulated by L-arginine infusion. Whether infusion of L-arginine at 100 mg\kg for 30 min leads to an increase in U Na and cGMP excretion could not be analysed, since only a few urine samples were obtained at the end of 30 min.
In conclusion, systemic administration of L-arginine represents a valid and safe non-invasive method for the assessment of endothelial function of the human renal vascular bed. A dose of L-arginine at 100 mg\kg for 30 min is preferable to that of 500 mg\kg for 30 min, since at the lower dose effects on the renal circulation can be analysed without confounding systemic haemodynamic or other non-specific effects. Furthermore, the present study highlights the importance of including D-arginine as a control in clinical studies examining the effects of L-arginine-induced vasodilation at higher doses.
